CHKB-CPT1B: A Promising Drug Target for Cancer (G386593)

Target Name: CHKB-CPT1B

NCBI ID: G386593

CHKB-CPT1B

Other Name(s): CHKB-CPT1B readthrough (NMD candidate) | CHKL-CPT1B | CPT1B | CPTI-M | CPT1-M

CHKB-CPT1B: A Promising Drug Target for Cancer

CHKB-CPT1B is a gene that encodes for a protein known as CPT1B. CPT1B is a key regulator of the DNA damage response, a critical pathway that helps the cell respond to DNA damage and ensure the integrity of its genetic material. Mutations in the CHKB gene have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, CPT1B has emerged as a promising drug target for a variety of diseases.

The CHKB gene and its associated proteins

The CHKB gene is located on chromosome 1p36 and encodes for a protein of the same name, CPT1B. CPT1B is a 24.5 kDa protein that plays a critical role in the DNA damage response. It is composed of a N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal T-loop domain. The N-terminal transmembrane domain gives CPT1B its unique ability to interact with DNA and other proteins, while the coiled-coil domain allows it to adopt a variety of conformations that affect its function. The C-terminal T-loop domain is responsible for the protein's stability and functions as a negative regulator of the DNA damage response.

The CHKB-CPT1B protein functions as a negative regulator of the DNA damage response. It interacts with the protein p53, which is a well-known regulator of the DNA damage response. When DNA damage occurs, p53 is recruited to the site of the damage and triggers the DNA damage response. CPT1B works to inhibit the activity of p53, preventing it from activating the DNA damage response. This is important because an incorrect activation of the DNA damage response can lead to a variety of negative consequences, including the development of cancer.

CPT1B's role in the DNA damage response

CPT1B is a key regulator of the DNA damage response. Its function in this process is to prevent the activation of p53, which is a well-known regulator of the DNA damage response. When DNA damage occurs, p53 is recruited to the site of the damage and triggers the DNA damage response. CPT1B works to inhibit the activity of p53, preventing it from activating the DNA damage response. This is important because an incorrect activation of the DNA damage response can lead to a variety of negative consequences, including the development of cancer.

CPT1B's role in cancer development

CPT1B is a key regulator of the DNA damage response and has been implicated in the development of a variety of cancers. Studies have shown that CPT1B mutations are frequently observed in tumors, and that these mutations can disrupt the normal function of CPT1B. The loss of CPT1B's DNA damage regulation function has been implicated in the development of a variety of cancers, including breast, ovarian, and colorectal cancers.

CPT1B's potential as a drug target

CPT1B's role in the DNA damage response makes it a promising drug target for a variety of diseases. The development of CPT1B inhibitors has been shown to be effective in a variety of cancer models, including breast, ovarian, and colorectal cancers. These inhibitors have been shown to disrupt the activity of p53, the protein responsible for the DNA damage response. By inhibiting the DNA damage response, CPT1B inhibitors have been shown to have a variety of potential therapeutic effects, including the inhibition of tumor growth and the regression of established cancer tumors.

Conclusion

CHKB-CPT1B is a gene that encodes for a protein known as CPT1B. CPT1B is a key regulator of the DNA damage response and has

Protein Name: CHKB-CPT1B Readthrough (NMD Candidate)

The "CHKB-CPT1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHKB-CPT1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets